Anti-CD47 Monoclonal Antibody–Drug Conjugate: A Targeted Therapy to Treat Triple-Negative Breast Cancers
Triple-negative breast cancers (TNBCs) are frequently recurrent due to the development of drug resistance post chemotherapy. Both the existing literature and our study found that surface receptor CD47 (cluster of differentiation 47) was upregulated in chemotherapy-treated TNBC cells. The goal of thi...
Main Authors: | Yingnan Si, Ya Zhang, Jia-Shiung Guan, Hanh Giai Ngo, Angela Totoro, Ajeet Pal Singh, Kai Chen, Yuanxin Xu, Eddy S. Yang, Lufang Zhou, Runhua Liu, Xiaoguang (Margaret) Liu |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-08-01
|
Series: | Vaccines |
Subjects: | |
Online Access: | https://www.mdpi.com/2076-393X/9/8/882 |
Similar Items
-
Monoclonal Antibodies and Antibody Drug Conjugates in Multiple Myeloma
by: Jakub Radocha, et al.
Published: (2021-03-01) -
Antibody–Drug Conjugate to Treat Meningiomas
by: Kai Chen, et al.
Published: (2021-05-01) -
Production of horseradish peroxidase conjugated monoclonal anti-heparan sulfate proteoglycans antibody for immunologic assay
by: Nittaya Chansiw, et al.
Published: (2008-09-01) -
Strategies to enhance monoclonal antibody uptake and distribution in solid tumors
by: Brandon M. Bordeau, et al.
Published: (2021-08-01) -
Monoclonal Antibodies to Treat Multiple Myeloma: A Dream Come True
by: Mattia D’Agostino, et al.
Published: (2020-11-01)